Abstract：
UNASSIGNED: Examine Bach1 protein expression in bone marrow biopsy specimens obtained from newly diagnosed multiple myeloma (NDMM) and iron deficiency anemia (IDA) patients. Conduct a thorough analysis to explore the potential connection between Bach1 and the onset as well as treatment response of NDMM.
UNASSIGNED: This study investigated Bach1 expression in bone marrow biopsy tissues from NDMM and IDA patients. Immunohistochemical staining and Image-pro Plus software were utilized for quantitatively obtaining the expression level of Bach1 protein. Arrange Bach1 expression levels from high to low, and use its median expression level as the threshold. Samples with Bach1 expression level above the median are categorized as the high-expression group, while those below the median are categorized as the low-expression group. Under this grouping, a detailed discussion was conducted to explore relationship of the Bach1 expression level with the patients\' gender, ISS stage, and survival rate based on the Bortezomib (Btz) therapy.
UNASSIGNED: Our experiment indicates that the expression level of Bach1 in NDMM patients is significantly higher than in IDA patients. Furthermore, we discovered that patients in the high-expression group exhibit better prognosis compared to those in the low-expression group after Btz-treatment. Bioinformatics analysis further confirms this conclusion.
UNASSIGNED: By categorizing Bach1 expression level as high and low, our study offers a unique perspective on understanding the relationship between Bach1 and NDMM.
UNASSIGNED: This study investigated Bach1 expression in bone marrow biopsy tissues from NDMM and IDA patients. Immunohistochemical staining and Image-pro Plus software were utilized for quantitatively obtaining the expression level of Bach1 protein. Arrange Bach1 expression levels from high to low, and use its median expression level as the threshold. Samples with Bach1 expression level above the median are categorized as the high-expression group, while those below the median are categorized as the low-expression group. Under this grouping, a detailed discussion was conducted to explore relationship of the Bach1 expression level with the patients\' gender, ISS stage, and survival rate based on the Bortezomib (Btz) therapy.
UNASSIGNED: Our experiment indicates that the expression level of Bach1 in NDMM patients is significantly higher than in IDA patients. Furthermore, we discovered that patients in the high-expression group exhibit better prognosis compared to those in the low-expression group after Btz-treatment. Bioinformatics analysis further confirms this conclusion.
UNASSIGNED: By categorizing Bach1 expression level as high and low, our study offers a unique perspective on understanding the relationship between Bach1 and NDMM.
摘要：
■检查从新诊断的多发性骨髓瘤（NDMM）和缺铁性贫血（IDA）患者获得的骨髓活检标本中Bach1蛋白的表达。进行全面分析，以探索Bach1与NDMM的发病和治疗反应之间的潜在联系。
■本研究调查了来自NDMM和IDA患者的骨髓活检组织中Bach1的表达。利用免疫组织化学染色和Image-proPlus软件定量获得Bach1蛋白的表达水平。排列Bach1表达水平从高到低，并使用其中值表达水平作为阈值。Bach1表达水平高于中位数的样品被归类为高表达组，而低于中位数的则被归类为低表达组。在这个分组下,进行了详细的讨论，以探讨Bach1表达水平与患者性别的关系，国际空间站阶段，和基于硼替佐米（Btz）治疗的生存率。
■我们的实验表明，NDMM患者中Bach1的表达水平明显高于IDA患者。此外，我们发现,在Btz治疗后,高表达组患者的预后优于低表达组.生物信息学剖析进一步证实了这一结论。
■通过将Bach1表达水平分类为高和低，我们的研究为理解Bach1和NDMM之间的关系提供了独特的视角。
■本研究调查了来自NDMM和IDA患者的骨髓活检组织中Bach1的表达。利用免疫组织化学染色和Image-proPlus软件定量获得Bach1蛋白的表达水平。排列Bach1表达水平从高到低，并使用其中值表达水平作为阈值。Bach1表达水平高于中位数的样品被归类为高表达组，而低于中位数的则被归类为低表达组。在这个分组下,进行了详细的讨论，以探讨Bach1表达水平与患者性别的关系，国际空间站阶段，和基于硼替佐米（Btz）治疗的生存率。
■我们的实验表明，NDMM患者中Bach1的表达水平明显高于IDA患者。此外，我们发现,在Btz治疗后,高表达组患者的预后优于低表达组.生物信息学剖析进一步证实了这一结论。
■通过将Bach1表达水平分类为高和低，我们的研究为理解Bach1和NDMM之间的关系提供了独特的视角。
